BCL2 and acute myeloid leukemia: In this contribution, we have designed and developed nanovehicles from poly(ethylene glycol)‐b‐poly(l‐boronophenylalanine‐co‐l‐tyrosine) (PEG‐b‐P(BPA‐co‐Tyr)) for efficient coencapsulation and responsive release of both BCL2 (ABT199) and MCL1 (TW37) inhibitors, achieving synergetic and potent treatment of AML (Scheme 1).